



## **CURRICULUM VITAE**

### **Tomas J. Philipson**

**OFFICE:** The University of Chicago  
The Irving B. Harris Graduate School of Public Policy Studies  
1155 E. 60th Street  
Chicago, IL 60637  
E-mail: t-philipson@uchicago.edu

#### **PROFESSIONAL EXPERIENCE**

*Senior Expert*, Compass Lexecon, 2016 – Present  
*Daniel Levin Professor of Public Policy*, University Of Chicago, Irving B. Harris Graduate School of Public Policy Studies, 1998 – Present  
*Director*, Health Economics, Becker Friedman Institute, 2015 – Present  
*Associate Faculty Member*, University of Chicago, Department of Economics, 1998 – Present  
*Senior Lecturer*, The Law School, University of Chicago, 1998 – 2006  
*Visiting Assistant Professor*, Yale University, Department of Economics, 1994  
*Assistant and Associate Professor*, University of Chicago, Department of Economics, 1990 – 1998  
*Post-Doctoral Fellow*, University of Chicago, Department of Economics, 1989

#### **PUBLIC SERVICE**

*Scientific Advisory Board*, 21<sup>st</sup> Century Cures, US House of Representatives, Health and Energy Committee, 2015  
*Commission Member*, National Key Indicator Commission (Appointed by Speaker of the US House of Representatives), December 2010  
*Senior Health Care Advisor*, Campaign of Senator John McCain for President of the United States, 2008  
*Senior Economic Advisor to the Administrator*, Centers for Medicare and Medicaid Services, 2004  
*Senior Economic Advisor to the Commissioner*, the Food and Drug Administration, 2003 – 2004

#### **PROFESSIONAL AFFILIATIONS**

Forbes Magazine, Op-ed Contributor, Tomas Philipson-The Health Care Economy.  
John M. Olin Program in Law & Economics, The Law School, University of Chicago, (1999-present)  
George J. Stigler Center, GSB, University of Chicago, Faculty Associate (1995-present)  
The Center for Health and Social Sciences, The University of Chicago, Steering Committee, (2004-present)  
The Milken Institute, Senior Fellow, (2004-present)

National Bureau of Economic Research (NBER), Faculty Research Fellow (1996-99), Research Associate (1999-present)  
Schaeffer Center for Health Policy and Economics, Fellow, University of Southern California, (2009-present)  
Chairman, Project FDA, Manhattan Institute (2008-present)  
American Enterprise Institute, Visiting Scholar, (2007-present)  
Senior Fellow, the Heartland Institute, (2007-present)  
Adjunct Staff, RAND Corporation, (2005-present)  
The World Bank, Research Fellow, (2003)  
Center for Poverty Research, University of Chicago, Faculty Associate (1996-present)  
Robert Wood Johnson Clinical Scholars Program, Core Faculty (1995-2002)  
Population Research Center-NORC, University of Chicago (1993-present)  
Scientific Advisory Board, Alliance for Potato Research and Education, (2011-)

## **PROFESSIONAL SERVICE**

**European Journal of Health Economics**, Editorial Board, (2009-2011)  
**Health Economics**, Editorial Board (2005-2013)  
**Forums in Health Economics and Health Policy**, Berkeley Electronic Press, Founding Co-Editor (2004-present)  
**Economic Inquiry**, Editorial Board (1996-2001)  
**University-wide Council on Research**, The University of Chicago, (1999-2002).  
**University Technology Transfer Office (UCTech)**, The University of Chicago, Faculty Advisory Committee, 2004-2010  
**Working Group, Making Markets for Vaccines**, Center for Global Development, Washington DC, (2003-2004)  
**Executive Committee, Scientific Committee**, 2006 Meetings, American Society for Health Economics (ASHE).  
**Executive Committee, Scientific Committee**, 2007 Meetings, International Health Economics Association (IHEA), Copenhagen, Denmark.  
**Executive Committee, Scientific Committee**, 2008 Meetings, American Society for Health Economics (ASHE)  
**Executive Committee, Scientific Committee**, 2009 Meetings, International Health Economics Association (IHEA), Beijing, China  
**Advisor, Kennedy Commission**, NICE, The UK Health Service, 2009  
**Advisory Committee on Personalized Medicine**, PCAST, the President of the United States, 2007.  
**Award Committee, The Kenneth J. Arrow Award**, International Health Economics Association, 2007-2012  
**Center for Medicine in The Public Interest**, Advisory Board, (2006-2010)  
**National AIDS Prevention Center**, UCSF, Scientific Advisory Board (1995-98)

## EDUCATION

The Wharton School and University of Pennsylvania, *MA and PhD., Economics* (1989)

- Recipient of the William Carey Prize for Outstanding Dissertation

Claremont Graduate School, *M.A., Mathematics* (1985)

- 4.0 GPA

Uppsala University, Sweden, *B.Sc. Mathematics* (1984)

- Expedited Graduation

## AWARDS

Finalist, *Annual Research Award*, National Institute for Health Care Management Foundation, 2010.

*The Garfield Award*, Research America, 2007

[Awarded for most influential health economics paper in a given year]

*Prêmio Haralambos Simeonidis*, Brazilian Economic Association, 2006

[Awarded for best paper in any field of economics in a given year]

*The Kenneth J. Arrow Award*, International Health Economics Association, 2006

[Awarded for best paper in the field of health economics in a given year]

*The Kenneth J. Arrow Award*, International Health Economics Association, 2000

[Awarded for best paper in the field of health economics in a given year]

*Group Recognition Award*, Office of the Commissioner, The Food And Drug Administration, 2004

*The Milken Institute Award for Distinguished Economic Research*, The Milken Institute, 2003

[Awarded to best paper in any field of economics in a given year]

Alfred P. Sloan Foundation. Research Fellow. (1996-98)

John M. Olin Foundation. Faculty Fellow. (1996-97)

Earhart Foundation. (1990, 1992-94)

Royal Swedish Academy of Sciences. (1988-89)

Marcus Wallenberg Foundation. (1985-86)

Mathematics Clinic, Claremont Graduate School. (1985)

Swedish-American Society. (1985)

Kallenberg Foundation. (1984-85)

University of Uppsala, Sweden. International Fellowship. (1984)

Engwall Foundation, Sweden. (1982-87)

## RESEARCH GRANTS

Center for Health and the Social Sciences

"The War on Cancer", 2009

"Me-too Innovation and Pharmaceutical Markets", 2005.

"Estimating the Welfare Effects of Alternative Liability Regimes", 2006.

"The Impact of Personalized Medicine on the Pharmaceutical Industry", 2007.

RAND Corporation, "Estimating the Welfare Effects of Alternative Liability Regimes", 2007.

National Institutes of Health, "The Economics of Terminal Care", 2007.

US Department of Agriculture, "Economics and Obesity", 2003.

The World Bank, "African Health Care Delivery", 2002-03.

National Institutes of Health (NIA P30 AG-12657-06) "The Growth in Obesity and Technological Change." (2000).

National Institutes of Health (NIA AG16494). "Old-Age Longevity and The Market for Long-Term Care." (1999-2002).

John M. Olin Foundation. "Population, Longevity, and Human Capital." Joint with Gary Becker, Edward Glaeser, and Kevin Murphy. (2000).

National Institutes of Health (NIA AG14897). "Old-Age Longevity and Insurance." (1997-98).

National Science Foundation (SBR-9709635). "Data Markets." (1997-2000).

George J. Stigler Center for The Study of The Economy and The State. (1993-2007).

John M. Olin Foundation. "The Formation of Preferences." Joint with Gary Becker, Casey Mulligan, and Kevin Murphy. (1996-2000).

National Science Foundation (SBR-9409917). "Trade Under Incomplete Information: An Empirical Examination for the Case of HIV." (1994-97).

National Institutes of Health (AHCPR HS 08066-02). "The Demand for Immunity and the Effects of Public Health." (1993-97).

Rockefeller Foundation. (1994).

Center for Disease Control. Joint with Karen Goldstein and Robert Daum. (1993-94).

## **PUBLICATIONS**

### **Economic Aspects of Longevity**

#### ***Books***

Philipson, T., A. Jena, and E. Sun, (2010), Longevity, and Inequality, American Enterprise Institute Press.

#### ***Papers***

Becker, G., T. Philipson, and R. Soares, (2005), "The Quantity and Quality of Life and The Evolution of World Inequality", American Economic Review, March, v 95, No 1, pp 277-291

Philipson, T., and Rodrigo R. Soares. "The Quantity of Life and the Welfare Cost of AIDS in Sub-Saharan Africa", G. López-Casasnovas, B. Rivera, and L. Currais, Editors, Health and Economic Growth: Findings and Policy Implications, MIT Press, Cambridge, 2005.

Geoffard, P-Y., and T. Philipson. "Pricing and R&D when Consumption Affects Longevity", The RAND Journal of Economics, v 33, No 1, Spring (2002), 85-95

Lakdawalla, D., and T., Philipson. "The Rise in Old Age Longevity and the Market for Long Term Care," American Economic Review, v 92, No 1, March (2002), pp 295-306.

Philipson, T. and R. Soares. (2002) "World Inequality and the Rise in Longevity", B. Pleskovic and N. Stern, Editors, Annual World Bank Conference on Development Economics 2001/2002, Oxford University Press, New York, 2002, p.245-259.

Cawley, J., and T. Philipson. "An Empirical Examination of Information Barriers to Trade in Longevity-Based Insurance." American Economic Review 89.4, September, (1999): 827-48.

Dow, W., T. Philipson, and X. Sala-I-Martin. "Longevity Complementarities Under Competing Risks." American Economic Review 89.5, December, (1999): 1357-1372.

Philipson, T., and G. Becker. "Old-Age Longevity and Mortality Contingent Claims." Journal of Political Economy 106.3 (1998): 550-574.

### ***Working papers***

- Egan, M., R. Koijen, C. Mulligan, and T. Philipson (2013) "Adjusting Measures of Economic Output for Health : Is the Business Cycle Countercyclical?" , NBER-WP.
- Jena, A., Mulligan, C., T., Philipson, and E. Sun, (2008) "The Value of Life in General Equilibrium", NBER Working Paper
- Becker, G., K. Murphy, and T. Philipson (2007) "The Value of Life Near Its End and Terminal Care", NBER Working Paper No.13333,
- Mullin, C., and T. Philipson (1997). "The Future of Old-Age Longevity: Competitive Pricing of Mortality Contingent Claims." NBER Working Paper # 6042

### **Data Markets**

#### ***Books***

- Philipson, T. 2000, Data Markets; The Production of Health Statistics. The University of Chicago Press, pre-publication contract, 2000.

#### ***Papers***

- Malani, A., and T. Philipson, (2010), "Is Medical R&D Different? The Output-Development Link and its Implications", NBER Working Paper.
- Philipson, T., "Issues in Identifying and Estimating External Treatment Effects" (2002), Quantitative Issues in Evaluating HIV-Prevention Programs. Edited by R. Brookmeyer, and E. Kaplan. Yale University Press, 223-240
- Philipson, T. (2001), "Data markets, Missing Data, and Incentive Contracting.", *Econometrica*, v 69, No 4 , 1099-1111.
- Philipson, T. , and A., Malani (1999) "Measurement Errors: A Principal Investigator-Agent Approach." *Journal of Econometrics* 91.2: 273-298.
- Philipson, T., and L. Hedges. (1998) "Subject Evaluation in Social Experiments." *Econometrica* 66.2: 381-409.
- Philipson, T., and J. DeSimone. (1997) "Experiments and Subject Sampling." *Biometrika* 84.3: 618-632.
- Philipson, T. (1997) "Data Markets and the Production of Surveys." *Review of Economic Studies* 64.1: 47-73.
- Philipson, T. "The Evaluation of New Health Care Technology: The Labor Economics of Statistics." *Journal of Econometrics* 76.1-2 (1997): 375-396.
- Philipson, T. "Social Welfare and Measurement of Segregation." *Journal of Economic Theory* 60.2 (1993): 322-332.

### ***Working papers***

- Philipson, T. "External Treatment Effects." NBER Technical Working Paper ,No 250, Cambridge, MA.

### **Economic Epidemiology and Public Health**

#### ***Books and Reviews***

- Philipson, T., (2006), "Economic Epidemiology", The New Economic Palgrave.
- Philipson, T. "Economic Epidemiology and Infectious Disease", chapter in Handbook of Health Economics. Edited by J. Newhouse and T. Culyer. New York: North-Holland, 2000.
- Philipson, T., and R. A. Posner. Private Choices and Public Health: An Economic Interpretation of the AIDS Epidemic. Cambridge, MA: Harvard University Press, 1993.

## ***Papers***

- Boozer, M., and T. Philipson, (2000), "Public Intervention into Markets with Asymmetric Information: An Empirical Examination for HIV." Journal of Human Resources, v 35 (3), 419-448.
- Mosler, K., and T. Philipson. "Specification Analysis in Mixed Hazard Models: Generalizations from the Demand for Vaccines." Statistical Papers 40 (1999): 37-54.
- Philipson, T., and W. Dow. "Assortative Matching and The Growth of Infectious Disease." Mathematical Biosciences 148.2 (1998):161-81.
- Geoffard, P-Y., and T. Philipson. "Disease Eradication: Private vs. Public Vaccination." American Economic Review 87.1, March, (1997): 222-230.
- Ahituv, A., J. Hotz, and T. Philipson. "The Responsiveness of the Demand for Condoms to the Local Prevalence of AIDS." Journal of Human Resources 31.4 (1996): 869-898.
- Geoffard, P-Y., and T. Philipson. "Rational Epidemics and Their Public Control." International Economic Review 37.3 (1996): 603-624.
- Philipson, T. "Private Vaccination and Public Health: An Empirical Examination for U.S. Measles." Journal of Human Resources 31.3 (1996): 611-630.
- Philipson, T., and R. A. Posner. "The Economic Epidemiology of Crime." Journal of Law & Economics 39.2 (1996): 405-436.
- Dow, W. H., and T. Philipson. "An Empirical Examination of Assortative Matching on the Incidence of HIV." Journal of Health Economics 15.6 (1996): 735-752.
- Goldstein, K. P., T. J. Philipson, H. Joo, and R. Daum. "The Effect of Epidemic Measles on Immunization Rates." Journal of American Medical Association 276.1 (1996): 56-60.
- Philipson, T. "The Welfare Loss of Disease and The Theory of Taxation." Journal of Health Economics 14.3 (1995): 387-396.
- Philipson, T., and R. Posner. "The Microeconomics of the AIDS Epidemic in Developing Countries." Population and Development Review 21.4 (1995): 835-849.
- Geoffard, P-Y., and T. Philipson. "The Empirical Content of Canonical Models of Infectious Disease." Biometrika 82 (1995): 1-14.
- Philipson, T., and R. A. Posner. "A Theoretical and Empirical Investigation of the Effects of Public Health Subsidies." The Quarterly Journal of Economics 110.2 (1995): 445-474.
- Philipson, T., and R. A. Posner. "Public Spending on Health Education." Journal of Law & Economics 37.1 (1994): 17-38.
- Philipson et al (2015), "The Social Value of Vaccines", forthcoming, Health Affairs
- Philipson et al (2015), "Hepatitis C and Sparing Livers", forthcoming, Health Affairs

## **Delivery of Healthcare Services**

### ***Books***

- Lakdawalla, D., A., Chandra, M. Chernew, D. Goldman, A. Jena, A. Malani, T. Philipson," *Best of both worlds: Uniting universal coverage and personal choice in health care*" American Enterprise Institute, August 2013.

### ***Papers***

- Koijen, R., T. Philipson, H. Uhlig, (2015), "Financial Health Economics", forthcoming, Econometrica.
- Tomas J. Philipson and George Zanjani,(2014) "Economic Analysis of Risk and Uncertainty Induced by Health Shocks: A Review and Extension". In: Mark J. Machina, W.Kip Viscusi, editors, Handbook of the Economics of Risk and Uncertainty. Vol 1, Oxford: North Holland, p. 453-491.
- Tomas J. Philipson, (2014), Medical innovation as Real "Health Insurance", p 143-47, *Portrait of A Health Economist: Bengt Jonson*, Edited by T Culyer and G Kobelt, The Swedish Institute for Health Economics, Lund, Sweden.

- Philipson, T., et al (2010), "Geographic Variations in Health Care: The Role of Private Markets", Brookings Papers on Economic Activity, The Brookings Institution, 325-355
- Philipson, T., and R., Posner (2009), "Anti-Trust Policy for the Non-Profit Sector", Journal of Law and Economics, v 52(1), 1-18.
- Lakdawalla, D., and T. Philipson (2006), "Non-Profit Production in Health Care and Industry Performance", Journal of Public Economics, v 90 (9), 1681-98.
- Malani, A., T. Philipson, and G. David, (2003), "Theories of Firm Behavior in the Nonprofit Sector: A Synthesis and Empirical Evaluation", *The Governance of Not for Profits*, edited by Edward Glasear, The National Bureau of Economic Research, Chicago: The University of Chicago Press, pp 181-215
- Philipson, T., (2000), "Asymmetric Information and the Not-for-Profit Sector: Does Its Output Sell at a Premium?" chapter 10 in " *The Changing Hospital Industry*. Edited by D., Cutler. National Bureau of Economic Research. Chicago: University of Chicago Press, 2001, pp 325-356
- Philipson, T. and D. Lakdawalla (2001), "Medical Care Output and Productivity in The Non-Profit Sector." *Medical Care Output and Productivity*. Edited by E. Berndt and. D. Cutler. National Bureau of Economic Research, Studies in Income and Wealth Volume 62, Chicago: University of Chicago, pp119-140
- Goldman, D., and Philipson, T., (2007) "Integrated Insurance Design in the Presence of Multiple Medical Technologies", American Economic Review, vol. 97(2), 425-433
- Philipson, T. J., Snider, J. T., Lakdawalla, D., Stryckman, B., & Goldman, D. (2013), "Impact of oral nutritional supplementation on hospital outcomes" *American Journal of Managed Care*, 19(2), 121-128.
- Goldman, D. and T. Philipson, (2014), "Five Myths About Cancer Care In America" Health Affairs, October Vol 33:1801-1804.
- Lakdawalla, D., J. Snider, D. Perlroth, C. LaVallee, M. Linthicum, T. Philipson, J. Partridge, P. Wischmeyer, (2014), "Can Oral Nutrition Supplements Improve Medicare Patient Outcomes in the Hospital?" *Forums for Health Economics and Policy*.
- D. Goldman, D. Lakdawalla, and T. Philipson, (2015), "Mortality Versus Survival In International Comparisons Of Cancer Care", *Health Affairs*, March 20.
- Stevens, W., T.J. Philipson, Z. Khan, J. MacEwan, M. Linthicum, and D. Goldman, (2015) "Cancer Mortality Reductions Were Greatest Among Countries Where Cancer Care Spending Rose The Most, 1995–2007", *Health Affairs* April, 34:562-570;
- Lakdawalla D, Shafrin J, Lucarelli C, Nicholson S, Khan ZM and Philipson TJ (2015), "Quality-Adjusted Cost Of Care: A Meaningful Way To Measure The Value Of Health Gains". Health Affairs. 2015. 34(4):555-651.
- Eber MR, Goldman DP, Lakdawalla DN, Philipson TJ, Pritchard D, Huesch M, Summers N, Linthicum MT, Sullivan J and Dubois RW. (2015), "Clinical Evidence Inputs to Comparative Effectiveness Research Could Impact the Development of Novel Treatments", Journal of Comparative Effectiveness Research.

### **The Economics of Obesity**

- Philipson, T., and R., Posner, (2003), "The Long Run Growth of Obesity as a Function of Technological Change, Perspectives in Biology and Medicine, v 46, No 3, 87-108. [NBER Working Paper # 7423]
- Lakdawalla, D., T. Philipson, and J., Bhattacharya, (2005) "Welfare Enhancing Technological Change and The Growth in Obesity", American Economic Review, v 95 (2), pp 253-257.
- Philipson, T., C. Dai, L. Helmchen, J. Variyam, (2004), "*The Economics of Obesity: A Report on The Workshop Held at USDA Economic Research Services*" USDA, Washington , DC

- Lakdawalla, D., and T. Philipson. (2006) "The Economics of Obesity." *Elgar Companion to Health Economics*, edited by A. Jones, pp 72-82
- Lakdawalla, D., and T. Philipson. (2007), "Labor Supply and Weight", Journal of Human Resources, v 42, No 1, Winter, pp 85-117.
- Philipson, T. and R. Posner (2011), "Economic Aspects of Obesity Policy", forthcoming, Handbook of Social Science on Obesity Research", edited by J Cawley, Oxford University Press
- Lakdawalla, D., and T. Philipson, (2009) "The Growth of Obesity and Technological Change: A Theoretical And Empirical Examination.", Economics and Human Biology. vol. 7(3), 283-293. [NBER Working Paper # 8946, September 2002],
- Philipson T., and R. Posner, (2008), "Is the Obesity Epidemic A Public Health Problem?", Journal of Economic Literature, v 46 (4), 972-982.
- Philipson, T., M. Lichtium, and J. Snider, (2014), "The Global Economic Burden of Malnutrition" forthcoming, Science.
- Philipson, T., M. Linthicum and J. Snider, "A Tutorial on Health Economics and Outcomes Research in Nutrition", Journal Parenteral and Enteral Nutrition, September, 2014
- Linthicum, M., J. Snider, R. Vaithianathan, Y. Wu, C. LaVallee, D. Lakdawalla, J. Benner, and T. Philipson,, (2014) "Economic Burden of Disease-Associated Malnutrition in China", Asia-Pacific Journal of Public Health, October.

### **Valuation of Medical Technologies**

- Lakdawalla, D., J. Shafrin, C. Lucarelli, S. Nicholson, Z. Khan, T. J. Philipson, (2015), "Quality-Adjusted Cost Of Care: A Meaningful Way To Measure Growth In Innovation Cost Versus The Value Of Health Gains", Health Affairs, April, 34:555-561;
- Philipson, T., (2014), "Does Paying for Cost-Effective Health Care Violate both Static and Dynamic Efficiency?" p 1-12, Nordic Journal of Health Economics.
- Philipson, T., and A. Jena (2014), "Value to Whom? How Much Are New Medical Treatments Worth?", Scientific American, p13-15.
- Philipson, T., and A. Jena (2005) "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs", Forum for Health Economics & Policy, Forum: Biomedical Research and the Economy: Article 3. [http://www.bepress.com/fhep/biomedical\\_research/3](http://www.bepress.com/fhep/biomedical_research/3)
- Jena, A., E. Sun, E. D. Goldman, D. Lakdawalla, T. Philipson. (2010) "An Economic Evaluation of the War on Cancer". Journal of Health Economics., vol 29(3), 333-346.
- Sun, E., A. Jena, D. Lakdawalla, C. Reyes, T. Philipson, and D. Goldman, (2010), "The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000", Forums in THE Health Economics & Policy, Volume 13, Issue 2, 1-20
- Philipson et al, (2012), "The Option Value of Innovative Treatments in Leukemia", forthcoming, AJMC.
- Snider, J., J. Romley, W. Vogt, and T. Philipson, "The Option Value of Innovation" , forthcoming, Forum for Health Economics & Policy.
- Tomas Philipson et al (2012) "Is US health care spending compared to EU worth it? The case of cancer" , Health Affairs, April. (Top 10 downloaded articles in 2012)
- Tomas Philipson et al (2012) " The Value of hope in oncology care", Health Affairs, April.
- Tomas Philipson et al (2012) " Willingness to pay for oncology care in the US" , Health Affairs, April.
- Tomas Philipson et al (2012) " Ex-ante valuation of coverage for oncology care" Health Affairs, April.
- Tomas Philipson et al (2012), " The Economic Value of Statin Therapy: Societal Perspective Based on Population Data in the United States" Health Affairs.



- Sood, N., P. Huckfeldt, T. Philipson, (2013), “Quantifying the Value of Personalized Medicines: Evidence from COX-2 Inhibitors”, Forum for Health Economics and Policy, Volume 16, Issue 1, Pages 101–122.
- Estimating the value of diagnostics: Evidence from COX-2 Inhibitors”, forthcoming, Value in Health.
- Jena, A.; Calfee, J; Mansley, E.; and Philipson, T. (2009) "Me-Too Innovation in Pharmaceutical Markets," Forums for Health Economics & Policy: Vol. 12 : Issue. 1, Article 5
- Grabowski, D., D. Lakdawalla, M. Chernew, D Goldman, T. Philipson (2012), “The Large Social Value Resulting From Use Of Statins Warrants Steps To Improve Adherence And Broaden Treatment” Health Affairs, v 31 (10).
- Yin, W., J. Penrod, R. Maclean, D.Lakdawalla, T. Philipson, (2012), “Value of Survival Gains in Chronic Myeloid Leukemia”, American Journal of Managed Care 257-65
- Sanchez, Y.,J.Penrod, X. Qiu, J.Romley, J.Thornton-Snider, and T. Philipson, (2012) ”The Option Value of Innovative Treatments”, American Journal of Managed Care , 265-78.
- Goldman, D. A. Jena, and T. Philipson,(2013) “The Value of Diagnostic Testing in Personalized Medicine”. Forums for Health Economics and Policy; 16(2): 121–133
- Basu, A., Jena, A. B., Goldman, D. P., Philipson, T. J., & Dubois, R. (2013), “Heterogeneity in Action: The Role of Passive Personalization in Comparative Effectiveness Research”, forthcoming, Health Economics.

### **Reimbursement for Medical Technologies**

- Basu, A., and T. Philipson, (2010),“The Impact of Comparative Effectiveness Research on Health and Health Care Spending”, Journal of Health Economics, vol. 30(4), 695-706
- Jena, A., and T. Philipson, (2008), “Cost-Effectiveness Analysis and Innovation”, Journal of Health Economics. vol 27(5), p 1224-1236, September.
- Jena, A., and T. Philipson, “Cost-Effectiveness as Price Controls”, (2007), Health Affairs, v 26, No 3, pp 696-705.
- Jena, A., and T. Philipson, Authors Response to Letters on “Cost-Effectiveness as Price Controls”, Health Affairs, September/October 2007; 26(5): 1506-1507
- Jena, A. and T. Philipson, (2012) “Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption”, Journal of Health Economics.
- Goldman, D. C. Gupta, N. Sood, and T. Philipson,”The Cost of Information and The Cost of Health Care : The Case of Personalized Medicine”, forthcoming, Health Affairs.
- Jena, A., T. Philipson, (2012),” Economic Issues Associated with Incorporating Cost- Effectiveness Analysis into Public Coverage Decisions in the United States”, pp 271-289, Ch11 in The Future of Healthcare Reform in the United States, edited by A. Malani and M. Schill, The University of Chicago Press: Chicago and London.
- Yang, L.; J. Penrod, N. Sood, S. Woodby, T. Philipson, (2012), “Dynamic Cost-Effectiveness of Oncology Drugs”, American Journal of Managed Care, 249-259.
- Basu, A., Goldman,D., and T. Philipson, (2014), ”Heterogeneity in Action: The Role of Passive Personalization in Comparative Effectiveness Research”, forthcoming, Health Economics.
- Hult, K., and T. Philipson (2013), “ Public Liabilities and Health Care Policy”, NBER WP. 18571
- Stevens, W., T. Philipson, Y. Wu, C. Chen, D. Lakdawalla, (2014), “A Cost Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer Therapies, Forum for Health Economics and Policy, Vol 17(1).
- Stomberg, C. , Philipson, T. , Albaugh, M. and Sood, N. (2013),”Utilization effects of Rx-OTC switches and implications for future switches”. Health, 5, 1667-1680.

## Medical Innovation & Regulation

### **Books:**

- Malani, A. and T. Philipson, (2010), "Government Regulation of Medical Products and Innovation", forthcoming, *Handbook on the Economics of the Biopharmaceutical Industry*, edited by P Danzon and S. Nicholson, Oxford University Press.
- Innovation and Medical Product Markets*, submitted to Harvard University Press, Fall 2007.

### **Papers:**

- Philipson, T., (2015), "Managing Risk in Drug Development: Financial Engineering to the Rescue?", Milken Institute Review, Third Quarter, pp 60-65.
- Jena, A., S. Mecoulan, and T. Philipson, (2012), "Should global health be tailored towards the rich? Altruism and efficient R&D for neglected diseases", forthcoming, Forums in Health Economics & Policy.
- Goldman, D., D. Lakdawalla, T. Philipson, J. Romley, (2010), "Innovation and Data Exclusivity", Health Affairs, January, v 30, pp 84-90.
- Goldman, D., D. Lakdawalla, and T. Philipson (2011), Market Exclusivity For Drugs: The Authors Reply Health Affairs. v 30 p 799.
- Philipson, T., E. Sun, D. Goldman, and A. Jena, (2012), "A Reexamination of the Costs of Medical R&D Regulation", *Frontiers in Health Policy Research*, National Bureau of Economic Research, in Forums for Health Economics and Policy, Volume 15, Issue 3, Pages 132-159.
- Philipson, T., E. Sun, and D. Goldman, (2009), "The Welfare Effects of Product Liability Preemption in Presence of The FDA", forthcoming, *The Economics of Regulation and Liability*, National Bureau of Economic Research, edited by Daniel Kessler and Andrei Shleifer, The University of Chicago Press, 1-41
- Jena, A., S. Mechoulan, S., and T. Philipson, (2010), "Altruism and Innovation in Health Care", Journal of Law & Economics, v 53, 496-518.
- Goldman, D., A. Jena, T. Philipson, and E. Sun (2008), "Drug Licenses: A New Model for Pharmaceutical Pricing, Health Affairs, v 271, No 1, pp 122-29.
- Philipson, T., and E. Sun, (2008) "Is The Food and Drug Administration Safe and Effective?" Journal of Economic Perspectives. vol. 22(1), pages 85-102
- T., Philipson, Berndt, E., A. Gottschalk, E. Sun, (2007), "A Cost-Benefit Analysis of The Food and Drug Administration", Journal of Public Economics, 1-46
- Berndt, E., A. Gottschalk, T. Philipson, M. Strobeck, (2005), "Industry Funding of the FDA: The Effects of PDUFA on Approval Times and Withdrawal Rates", Nature, July, v4, p 545-554.
- Lakdawalla, D., and T. Philipson, (2012) "Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets", Journal of Law & Economics, v 55 (February 2012) pp 151-187. (NBER Working Paper #12577)
- Berndt, E., A. Gottschalk, T. Philipson, M. Strobeck, (2004), "Assessing The Impact of the The Prescription Drug Use Fee Acts (PDUFA) on the FDA Approval Process", *Frontiers in Health Policy Research*, Volume 8, Paper 2, National Bureau of Economic Research, in Forums for Health Economics and Policy, Berkeley Electronic Press, 1-33
- Philipson, T., (2004), "The Long Term Ramifications of Re-importation for the Health Care System", Managed Care, p 17-18.
- Lichtenberg, F., and T. Philipson, (2003), "The Dual Effects of Intellectual Property Regulations: Within and Between Patent Competition in The US Pharmaceutical Industry", The Journal of Law & Economics, October, Vol 45, 643-672
- Philipson, T., (2003), "The Regulation of Medical Innovation and Pharmaceutical Markets" The Journal of Law & Economics. October, S 1-5.

- Egan, M. and T. Philipson, (2013) “ International Health Economics”, NBER WP 19280.
- Et.al and Philipson, (2015) "The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)", Journal of National Cancer Institute, . pp 107-12.
- Lo, A., T. Philipson and A. Von Eschebach, (2015)” Health, Wealth, and 21st Century Cures”, forthcoming, Journal of American Medical Association.
- Seth A. Seabury\*, Dana P. Goldman, Charu N. Gupta, Zeba Khan, Amitabh Chandra, Tomas J. Philipson and Darius Lakdawalla, (2015), “Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection”, forthcoming, Forum for Health Economics and Policy.

## **Other Topics**

### ***Papers:***

- Philipson, T., and J. Snyder. “Equilibrium and Efficiency in an Organized Vote Market.” Public Choice 89.3-4 (1996): 245-265.
- Philipson, T. “The Exchange and Allocation of Decision Power.” Theory and Decision 33.3 (1992): 191-206.
- Philipson, T. “Social Monopoly Pricing and School Desegregation.” Rationality and Society 4 (1992): 189-199.
- Philipson, T. “Dynamic Information Release.” Journal of Economics 53.2 (1991): 205-213.

### ***Working Papers:***

- Mulligan, C., and T., Philipson. (2003) “A Positive Theory of Uninsurance”, mimeo, The University of Chicago.
- Mulligan, C., and T., Philipson. “Paternalism and Government Intervention: Public Finance in Reverse.” National Bureau of Economic Research Working Paper #7698, 2000.
- Philipson, T., and G. Zanjani. “Consumption vs Production of Insurance.” National Bureau of Economic Research Working Paper #6225, 1997.

## **Non-Refereed Publications**

### ***Solicited Papers, Book Chapters, Non-Refereed Proceedings, and Reviews:***

- Eber, M. D. Goldman, D. Lakdawalla, and T. Philipson (2012) “When Epidemiology Goes Astray: Valuing Cancer Care In The United States And Europe” *Health Affairs*, May.
- Goldman, D., D. Lakdawalla, T. Philipson, W. Yin, (2010) ”Valuing Health Technologies at NICE: Recommendations for improved incorporation of treatment value in HTA”, Editorial, *Health Economics*, v19(10), 1109-1116
- Jena, A., E. Sun, E. D. Goldman, D. Lakdawalla, T. Philipson. (2009) “An Economic Evaluation of the War on Cancer”. *VOX*, January 11, 2009, vol 29(3), 333-346
- Philipson, T., and E. Sun, (2008), “Regulating The Safety and Efficacy of Prescription Drugs”, *VOX*, <http://www.voxeu.org/index.php?q=node/804>.
- Comment on "Personal Decisions are the Leading Cause of Death" by Ralph Keeney, *Operations Research*, Vol. 56, No. 6, November/December 2008
- Philipson, T., “Commentary”, *Managerial and Decision Economics*, (2007), v 28, 453-454, 467-468.
- Philipson, T., A. Jena, E. Sun, “The Institute of Medicine Report on The FDA: Where is The Science?”, Editorial, *Health Economics*, v 16, 219-222, 2007.
- Philipson, T., E. Berndt, A Gottschalk, M. Strobeck, (2006), “How Safe Is Too Safe? Public Safety vs Innovation at The FDA”, *The Milken Review*, No 2, p 38-46.

- Philipson, T., and A. Jena, (2006), "Dividing The Benefits from Medical Breakthroughs", *The Milken Review*, v \*, No 1, pp-46-56.
- Philipson, T., "Within vs Between Patent Competition in The US Pharmaceutical Industry", *CATO Journal of Regulation*, 2004, v 26 (3), 42-48
- Philipson, T., (2003) "The Quality of Care through Managed Care: A Misguided Policy Debate?", *Journal of Legal Studies*, v 30(2)
- Philipson, T., (2001), "The World-Wide Growth of Obesity: An Economic Research Agenda", Invited Guest Editorial, *Health Economics*, v 10, pp 1-7.
- Lakdawalla, D., and T. Philipson, (2001), "Public Financing and The Market for Long-Term Care", *Frontiers in Health Policy Research*, Volume 4, National Bureau of Economic Research, edited by A. Garber, The University of Chicago Press, p 77-94
- Philipson, T., and G. Zanjani, (1999), "The Production and Regulation of Health Insurance: Limiting Opportunism under Asymmetric Information", in *Individual Decisions for Health*, edited by Bjorn Lindgren, Lund University Press, Sweden
- Philipson, T., R. Posner, and J. Wright. "Why AIDS Prevention Programs Do Not Work." *National Academy of Sciences & Institute of Medicine*, (1994): 19-28.
- Philipson, T., and T. Lawless. "Multiple Output Agency Incentives in Data Production: Experimental Evidence." *European Economic Review* 41 (1997): 959-973.
- Philipson, T. "Economic Epidemiology and Public Health." In *New Economics of Human Behavior: Essays in Honor of Gary Becker*, edited by M., Tommasi and K., Ierulli. Cambridge: Cambridge University Press, 1995: 216-235.
- Philipson, T. "Rational Public Health Policy." *Journal of Policy Analysis and Management* 14.3 (1995): 493-498.
- Philipson, T. "Public Sector Screening for Infectious Disease." In *Modeling the AIDS Epidemic: Planning, Policy, and Prediction*. Edited by M. Brandeau and E. Kaplan. ORSA, Raven Press, 1994: 109-122.
- Philipson, T., and R. Posner. "The Logic of Rational Choice, Public Policy, and AIDS." *Rationality and Society* 8.4 (1996): 497-504.
- Philipson, T., and R. Posner. "Sexual Behavior, Disease, and Fertility Risk." *Risk, Decision, and Policy* 1.1 (1996): 1-14.
- Heckman, J., and T. Philipson. "Evaluation of an Affirmative Action Argument." *Rationality and Society* 4 (1992): 360-365.
- Philipson, T. "The Bayesian Model of Conditional Preference and Trade Under Uncertainty." In *Decision Making Under Risk and Uncertainty: New Models and Empirical Findings*. John Geweke, Editor. Kluwer Academic Press, 1991: 100-106.

## **SELECTED COVERAGE OF RESEARCH IN POPULAR MEDIA**

### ***Television/Radio:***

- CSPAN, Coverage of panel debating book "Best of both worlds", Aug 6 2013
- BIO Super Session, "The Future of Global Innovation", Chicago, Apr 24, 2013.
- TED-MED, "The Economics of Oncology Innovation", Washington DC, April 16, 2013
- BioCentury, CBS, profile of various selected works, June 2012.
- National Public Radio (NPR), segment on Philipson's paper "Value of Hope in Cancer Care" April 9, 2012.
- Fox News, Segment on Philipson's paper "Cost of Caution", June 21, 2010
- Chicago Public Radio, Interviewed on The Obama Health Care Plan, September 10, 2009.

National Public Radio (NPR), Interviewed on The Obama Health Care Plan, August 21, 2009.  
Chicago Public Television, Interviewed on The Obama Health Care Plan, Chicago Tonight, Aug 18, 2009.  
Bloomberg Radio, Interviewed on Economics of Obesity, On the Economy with Tom Keene, July 16, 2008.  
Bloomberg TV, Interviewed on Economics of Obesity, Money and Politics, November 23, 2007.  
National Public Radio (NPR), Market-watch, Interview regarding results of Lakdawalla and Philipson “*The Growth in Obesity and Technological Change: A Theoretical and Empirical Examination.*” On program, March, 2007.  
CSPAN, Presentation of Lakdawalla and Philipson “*The Growth of Obesity and Technological Change: An Theoretical and Empirical Examination.*” June, 2003.  
National Public Radio (NPR), Program on Lakdawalla and Philipson (2002) “*The Growth of Obesity and Technological Change: An Theoretical and Empirical Examination.*” July 2002.  
FOX News, Report on Philipson and Posner “*The Long Run Growth of Obesity as a Function of Technological Change.*”, June 9, 2000.  
CNN, World News, Report on Philipson and Posner “*The Long Run Growth of Obesity as a Function of Technological Change.*”, June 14, 2000.

## **EXPERT RETENTION, REPORTS, AND TESTIMONY**

### **Consultant Retention:**

Work under Lexecon and Analysis Group 2004-2007: Client (Law firm)  
2005-2006: Bayer AG (Bartlit Beck), Bristol Myers Squib (Cravath Swaine)  
Johnson & Johnson (Gibson Dunn), Medtronic (McDermott Will)  
McKesson (Morrison & Foerster), Lorillard (Shook Hardy & Bacon)  
Guidant (Skadden Arps) Schering-Plough (Wachtell Lipton)  
2007: Eli Lilly (Pepper Hamilton), Abbott (Wildman Harrold), Merck (Bartlit Beck)

### **Amicus Briefs:**

In Re: *Federal Trade Commission v. Activis Inc.*, US Supreme Court, Amicus brief 12-416 filed March, 2013.  
In Re: *Federal Trade Commission v. Phoebe Putney Health System Inc.*, US Supreme Court, Amicus brief 11-1160 filed Aug 20, 2012.  
In Re: *Wyeth vs Levine*, US Supreme Court, Amicus Brief filed May 2008.  
In Re: *State of Florida vs US Department of Health and Human Services*, US Supreme Court, Amicus Brief 11-400 filed January 17, 2012.  
In Re: *National Federation of Independent Business vs US Department of Health and Human Services*, US Supreme Court, Amicus Brief 11-393 filed January 2012.

### **Expert Retention:**

In Re: *Anthony Gallegos v Dick Simon Trucking*, No 980902978 PI, Third District Court of Salt lake County, Utah, 980902978PI, Declaration, September 2001.  
In Re *Dorethea Pavlov v. Continental Casual Company*, US District Court , Northern District of Ohio, 5:07cv2580, Declaration Sept 2008. Deposition, October 2008.

In Re: *State of Texas v Alpharma*, US District Court, Travis County, TX, D-1GV-08 00 15 66, Declaration, June, 2010, Deposition July, 2010. Sur-rebuttal October, 2010. Court Testimony January, 2011.

In Re: *Amgen Inc v Teva Pharmaceuticals*, US District Court, Eastern District of Pennsylvania, No 2:09-cv-05675-SD, Declaration, March , 2011.

In Re: *Donovan v Philips Morris USA*, US District Court for the District of Massachusetts, MA, No 06cv1223u-NG, Declaration May 2011.

In Re: *The United States of America v Davita* , US District Court Eastern District of Texas, 1:05-CV-00227. Conducted an economic analysis of the defendant's billing practices with public payers. June 2011.

In Re: *Optum v 3M*, declaration to the Federal Trade Commission, conducted economic analysis of the effects on US health care from anti-competitive practices in hospital billing. February 2012.

In Re: *Baxter vs Johnson & Johnson*, United States International Trade Commission, No. 337-TA-91, Declarations Oct & Nov 2014, Court Testimony, International Trade Commission , Feb 2015.

In Re: *Amgen v Sandoz*, US District Court for the Northern District of California, No. 3:14-cv-04741-RS, Declaration, Feb 2015.

#### **CONSULTANT AND NON-ACADEMIC APPOINTMENTS**

**Founding Partner**, Precision Health Economics LLC. (Acquired 2015 by Precision for Medicine LLC)

**Board Member**, PACE Council, Eli Lilly, 2012-present

**Associate**, Goldman Sachs, New York (1987).

**Honorary Board of Directors**, The Round Table Group (<http://www.roundtablegroup.com>), Chicago (1997-).